{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:20:11Z","timestamp":1781594411083,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41401-020-00517-z","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T08:03:01Z","timestamp":1600934581000},"page":"1416-1426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["\u03b1-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in mice"],"prefix":"10.1038","volume":"41","author":[{"given":"Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-fei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-zhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-qian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-nian","family":"Shou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-yan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"517_CR1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/med.21463","volume":"38","author":"PP Zheng","year":"2018","unstructured":"Zheng PP, Li J, Kros JM. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: critical research-practice gaps, challenges, and insights. Med Res Rev. 2018;38:325\u201376.","journal-title":"Med Res Rev"},{"key":"517_CR2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2019.01.038","volume":"280","author":"M Totzeck","year":"2019","unstructured":"Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology\u2014strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280:163\u201375.","journal-title":"Int J Cardiol"},{"key":"517_CR3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJM199103213241210","volume":"324","author":"JH Doroshow","year":"1991","unstructured":"Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med. 1991;324:843\u20135.","journal-title":"N Engl J Med"},{"key":"517_CR4","doi-asserted-by":"crossref","first-page":"e1925","DOI":"10.1097\/MJT.0000000000000430","volume":"23","author":"ME Roth","year":"2016","unstructured":"Roth ME, Muluneh B, Jensen BC, Madamanchi C, Lee CB. Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma. Am J Ther. 2016;23:e1925\u20138.","journal-title":"Am J Ther"},{"key":"517_CR5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/1556-4029.13633","volume":"63","author":"DR Matson","year":"2018","unstructured":"Matson DR, Accola MA, Rehrauer WM, Corliss RF. Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab. J Forensic Sci. 2018;63:954\u20137.","journal-title":"J Forensic Sci"},{"key":"517_CR6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijcard.2019.05.028","volume":"292","author":"V Quagliariello","year":"2019","unstructured":"Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, et al. Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor pembrolizumab associated to trastuzumab. Int J Cardiol. 2019;292:171\u20139.","journal-title":"Int J Cardiol"},{"key":"517_CR7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-018-0034-2","volume":"18","author":"CM Crosby","year":"2018","unstructured":"Crosby CM, Kronenberg M. Tissue-specific functions of invariant natural killer T cells. Nat Rev Immunol. 2018;18:559\u201374.","journal-title":"Nat Rev Immunol"},{"key":"517_CR8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-immunol-032713-120243","volume":"32","author":"M Salio","year":"2014","unstructured":"Salio M, Silk JD, Jones EY, Cerundolo V. Biology of CD1- and MR1-restricted T cells. Annu Rev Immunol. 2014;32:323\u201366.","journal-title":"Annu Rev Immunol"},{"key":"517_CR9","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.4049\/jimmunol.178.5.2706","volume":"178","author":"NA Nagarajan","year":"2007","unstructured":"Nagarajan NA, Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol. 2007;178:2706\u201313.","journal-title":"J Immunol"},{"key":"517_CR10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nri2904","volume":"11","author":"SP Berzins","year":"2011","unstructured":"Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. 2011;11:131\u201342.","journal-title":"Nat Rev Immunol"},{"key":"517_CR11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ijc.20998","volume":"116","author":"JW Molling","year":"2005","unstructured":"Molling JW, Kolgen W, van der Vliet HJ, Boomsma MF, Kruizenga H, Smorenburg CH, et al. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer. 2005;116:87\u201393.","journal-title":"Int J Cancer"},{"key":"517_CR12","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1200\/JCO.2006.08.5787","volume":"25","author":"JW Molling","year":"2007","unstructured":"Molling JW, Langius JA, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJ, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol. 2007;25:862\u20138.","journal-title":"J Clin Oncol"},{"key":"517_CR13","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.0800126","volume":"182","author":"S Motohashi","year":"2009","unstructured":"Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A phase I-II study of alpha-galactosylceramide-pulsed IL-2\/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009;182:2492\u2013501.","journal-title":"J Immunol"},{"key":"517_CR14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20042592","volume":"201","author":"DH Chang","year":"2005","unstructured":"Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005;201:1503\u201317.","journal-title":"J Exp Med"},{"key":"517_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-007-0373-5","volume":"57","author":"T Uchida","year":"2008","unstructured":"Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, et al. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother. 2008;57:337\u201345.","journal-title":"Cancer Immunol Immunother"},{"key":"517_CR16","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-04-1453","volume":"11","author":"A Ishikawa","year":"2005","unstructured":"Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005;11:1910\u20137.","journal-title":"Clin Cancer Res"},{"key":"517_CR17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2003-04-1155","volume":"103","author":"M Nieda","year":"2004","unstructured":"Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood. 2004;103:383\u20139.","journal-title":"Blood"},{"key":"517_CR18","first-page":"3702","volume":"8","author":"G Giaccone","year":"2002","unstructured":"Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002;8:3702\u20139.","journal-title":"Clin Cancer Res"},{"key":"517_CR19","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1158\/1078-0432.CCR-06-0114","volume":"12","author":"S Motohashi","year":"2006","unstructured":"Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2006;12:6079\u201386.","journal-title":"Clin Cancer Res"},{"key":"517_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms5602","volume":"5","author":"HC Chuang","year":"2014","unstructured":"Chuang HC, Sheu WH, Lin YT, Tsai CY, Yang CY, Cheng YJ, et al. HGK\/MAP4K4 deficiency induces TRAF2 stabilization and Th17 differentiation leading to insulin resistance. Nat Commun. 2014;5:4602.","journal-title":"Nat Commun"},{"key":"517_CR21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/eurheartj\/ehx261","volume":"39","author":"H Xiao","year":"2018","unstructured":"Xiao H, Li H, Wang JJ, Zhang JS, Shen J, An XB, et al. IL-18 cleavage triggers cardiac inflammation and fibrosis upon beta-adrenergic insult. Eur Heart J. 2018;39:60\u20139.","journal-title":"Eur Heart J"},{"key":"517_CR22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/CIRCULATIONAHA.117.030742","volume":"138","author":"MM Gladka","year":"2018","unstructured":"Gladka MM, Molenaar B, de Ruiter H, van der Elst S, Tsui H, Versteeg D, et al. Single-cell sequencing of the healthy and diseased heart reveals cytoskeleton-associated protein 4 as a new modulator of fibroblasts activation. Circulation. 2018;138:166\u201380.","journal-title":"Circulation"},{"key":"517_CR23","first-page":"58114","volume":"23","author":"L Aronoff","year":"2018","unstructured":"Aronoff L, Epelman S, Clemente-Casares X. Isolation and identification of extravascular immune cells of the heart. J Vis Exp. 2018;23:58114.","journal-title":"J Vis Exp"},{"key":"517_CR24","doi-asserted-by":"crossref","first-page":"19877","DOI":"10.1074\/jbc.RA119.010943","volume":"294","author":"X Qu","year":"2019","unstructured":"Qu X, Liu Y, Cao D, Chen J, Liu Z, Ji H, et al. BMP10 preserves cardiac function through its dual-activation of SMAD-mediated and STAT3-mediated pathways. J Biol Chem. 2019;294:19877\u201388.","journal-title":"J Biol Chem"},{"key":"517_CR25","doi-asserted-by":"publisher","unstructured":"Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol. 2008; Chapter 14:Unit 14.1.\u00a0https:\/\/doi.org\/10.1002\/0471142735.im1401s83.","DOI":"10.1002\/0471142735.im1401s83"},{"key":"517_CR26","doi-asserted-by":"crossref","DOI":"10.1038\/srep02559","volume":"3","author":"T Ando","year":"2013","unstructured":"Ando T, Ito H, Ohtaki H, Seishima M. Toll-like receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes. Sci Rep. 2013;3:2559.","journal-title":"Sci Rep"},{"key":"517_CR27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140:80\u201391.","journal-title":"Circulation"},{"key":"517_CR28","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","volume":"116","author":"DL Mann","year":"2015","unstructured":"Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254\u201368.","journal-title":"Circ Res"},{"key":"517_CR29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11:255\u201365.","journal-title":"Nat Rev Cardiol"},{"key":"517_CR30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mam.2018.07.001","volume":"65","author":"NG Frangogiannis","year":"2019","unstructured":"Frangogiannis NG. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Asp Med. 2019;65:70\u201399.","journal-title":"Mol Asp Med"},{"key":"517_CR31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00395-014-0449-2","volume":"109","author":"K Savvatis","year":"2014","unstructured":"Savvatis K, Muller I, Frohlich M, Pappritz K, Zietsch C, Hamdani N, et al. Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis. Basic Res Cardiol. 2014;109:449.","journal-title":"Basic Res Cardiol"},{"key":"517_CR32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41577-018-0065-8","volume":"18","author":"FK Swirski","year":"2018","unstructured":"Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018;18:733\u201344.","journal-title":"Nat Rev Immunol"},{"key":"517_CR33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCRESAHA.115.307778","volume":"118","author":"AR Pinto","year":"2016","unstructured":"Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT, D\u2019Antoni ML, Debuque R, et al. Revisiting cardiac cellular composition. Circ Res. 2016;118:400\u20139.","journal-title":"Circ Res"},{"key":"517_CR34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/CIRCRESAHA.118.314028","volume":"124","author":"G Bajpai","year":"2019","unstructured":"Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, et al. Tissue resident CCR2\u2212 and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ Res. 2019;124:263\u201378.","journal-title":"Circ Res"},{"key":"517_CR35","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1161\/01.RES.0000163017.13772.3a","volume":"96","author":"O Dewald","year":"2005","unstructured":"Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, et al. CCL2\/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res. 2005;96:881\u20139.","journal-title":"Circ Res"},{"key":"517_CR36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cell.2017.03.050","volume":"169","author":"M Hulsmans","year":"2017","unstructured":"Hulsmans M, Clauss S, Xiao L, Aguirre AD, King KR, Hanley A, et al. Macrophages facilitate electrical conduction in the heart. Cell. 2017;169:510\u201322.e20.","journal-title":"Cell"},{"key":"517_CR37","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/cvr\/cvu062","volume":"102","author":"S Van Linthout","year":"2014","unstructured":"Van Linthout S, Miteva K, Tschope C. Crosstalk between fibroblasts and inflammatory cells. Cardiovasc Res. 2014;102:258\u201369.","journal-title":"Cardiovasc Res"},{"key":"517_CR38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K","volume":"20","author":"C Tan","year":"1967","unstructured":"Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20:333\u201353.","journal-title":"Cancer"},{"key":"517_CR39","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","volume":"25","author":"X Xu","year":"2019","unstructured":"Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, et al. NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. Clin Cancer Res. 2019;25:7126\u201338.","journal-title":"Clin Cancer Res"},{"key":"517_CR40","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"},{"key":"517_CR41","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077\u201384.","journal-title":"N Engl J Med"},{"key":"517_CR42","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","volume":"74","author":"S Ganatra","year":"2019","unstructured":"Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives. J Am Coll Cardiol. 2019;74:3153\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"517_CR43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccl.2019.07.008","volume":"37","author":"S Ganatra","year":"2019","unstructured":"Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of immune therapy. Cardiol Clin. 2019;37:385\u201397.","journal-title":"Cardiol Clin"},{"key":"517_CR44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"517_CR45","doi-asserted-by":"crossref","first-page":"e0172412","DOI":"10.1371\/journal.pone.0172412","volume":"12","author":"E Miyaki","year":"2017","unstructured":"Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, et al. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus. PLoS One. 2017;12:e0172412.","journal-title":"PLoS One"},{"key":"517_CR46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","volume":"26","author":"MJ Wolf","year":"2014","unstructured":"Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26:549\u201364.","journal-title":"Cancer Cell"},{"key":"517_CR47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.yjmcc.2013.06.004","volume":"62","author":"T Homma","year":"2013","unstructured":"Homma T, Kinugawa S, Takahashi M, Sobirin MA, Saito A, Fukushima A, et al. Activation of invariant natural killer T cells by alpha-galactosylceramide ameliorates myocardial ischemia\/reperfusion injury in mice. J Mol Cell Cardiol. 2013;62:179\u201388.","journal-title":"J Mol Cell Cardiol"},{"key":"517_CR48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/cvr\/cvy164","volume":"115","author":"HX Wang","year":"2019","unstructured":"Wang HX, Li WJ, Hou CL, Lai S, Zhang YL, Tian C, et al. CD1d-dependent natural killer T cells attenuate angiotensin II-induced cardiac remodelling via IL-10 signalling in mice. Cardiovasc Res. 2019;115:83\u201393.","journal-title":"Cardiovasc Res"},{"key":"517_CR49","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.RES.65.3.657","volume":"65","author":"IJ Benjamin","year":"1989","unstructured":"Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res. 1989;65:657\u201370.","journal-title":"Circ Res"},{"key":"517_CR50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2018.03.041","volume":"828","author":"G Zhang","year":"2018","unstructured":"Zhang G, Zhang X, Li D, Tian J, Jiang W. Long-term oral atazanavir attenuates myocardial infarction-induced cardiac fibrosis. Eur J Pharmacol. 2018;828:97\u2013102.","journal-title":"Eur J Pharmacol"},{"key":"517_CR51","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/CIRCRESAHA.112.270132","volume":"111","author":"MA Sobirin","year":"2012","unstructured":"Sobirin MA, Kinugawa S, Takahashi M, Fukushima A, Homma T, Ono T, et al. Activation of natural killer T cells ameliorates postinfarct cardiac remodeling and failure in mice. Circ Res. 2012;111:1037\u201347.","journal-title":"Circ Res"}],"updated-by":[{"DOI":"10.1038\/s41401-021-00802-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000}}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00517-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00517-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00517-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T10:06:03Z","timestamp":1637057163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00517-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-00517-z","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41401-021-00802-5","URL":"https:\/\/doi.org\/10.1038\/s41401-021-00802-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}